- Display 15 Products per page
Published: June 1, 2004 | Price: $3,500.00 – $7,000.00
In 2003, the market for monoclonal antibodies in the treatment of cancer is just short of $2.8 billion and growing at a phenomenal rate. The market is fueled by leading products such as Rituxan and Herceptin; however, other products continue to demand more attention each year. This study reviews market data for the years 2001 to the present and forecasts the market to 2008, including Kalorama’s estimates of the competitive market share in 2008 based on the current pipeline and...Published: July 1, 2004 | Price: $3,500.00 – $7,000.00
New technologies and alternatives to traditional cosmetic surgery have opened up a huge new market for anti-aging products. Cosmetic facial rejuvenation is no longer the purview of plastic surgeons, but represents a booming cash business for a large number of dermatologist and other practitioners. Botox, dermal fillers, resurfacing modalities, lasers, and other alternatives are creating a dynamic and growing marketplace and finding millions of eager patients. This 400-page report examines the competing technologies, procedures, and options available to physicians, non-physician...Published: July 1, 2004 | Price: $3,500.00 – $7,000.00
After decades of sustained growth and profitability, the pharmaceutical industry has been positioned as one of the few recession proof industries based on its performance through multiple economical cycles. In recent years, there have been visible strains in the pharmaceutical business. With a downturn in fortunes, many pharmaceutical companies are searching for business solutions to streamline operations and cut costs as they strive to continue generating above-average shareholder returns. Outsourcing has become an integral, ongoing element of pharmaceutical companies’ business...Published: July 1, 2004 | Price: $895.00 – $1,790.00
Alternative routes of administration for insulin has been one of the leading drivers of drug delivery industry. Although transdermal and transmucosal systems have shown promise and true oral delivery remains a goal, pulmonary delivery has emerged as the leading area of development. Several major players in the pharmaceutical industry have given their backing to inhaled insulin projects, and product launches are imminent. However, the exact make-up of the market, patient acceptance, and regulatory progress are still not completely clear. This...Published: August 1, 2004 | Price: $895.00 – $1,790.00
After years of neglect, concerns over pain, how it is assessed and managed on a patient-by-patient basis have captured the attention of health care professionals and the public. There are a variety of issues that have acted to draw this attention, including the high prevalence of pain, continuing evidence that pain is undertreated and a growing awareness of the negative consequences of poor pain management. Infusion pumps were first introduced in the 1960s. These devices ushered in a whole new...Published: August 1, 2004 | Price: $995.00 – $1,910.00
Blood banking has been the most dynamic testing segment to adopt molecular diagnostics approaches since their introduction. Screening for HIV, HCV and HBV in donated blood, plasma and organs has largely been done by immunoassay procedures. In conjunction with background screening, this has become a very effective approach toward guaranteeing the safety of the blood/organ supply. However, there is a lag time between infection with these viruses and the production of antibodies against them. In some cases, such as HBV,...Published: August 1, 2004 | Price: $3,500.00 – $7,000.00
This Kalorama Information report focuses on current and emerging immunomodulators for cancer. The report covers both current and emerging cancer immunomodulators in detail. The report includes statistical information for cancers by type worldwide, with special emphasis on the U.S. market. Specifically, cancers where there are current products available or are in development are profiled. These include bladder, breast, colorectal, head/neck, kidney, lung, ovarian, pancreatic, and prostate cancers, as well as leukemia, lymphoma, melanoma, multiple myeloma, and neuroblastoma. The current market...Published: August 1, 2004 | Price: $1,995.00 – $5,990.00
The market for OTC Gastrointestinal products has gone through several significant changes in the past 5 years, most of which have to do with the Rx-to-OTC switches of two types of gastroesophageal reflux disease (GERD) drugs: H2 receptor antagonists and proton pump inhibitors (PPIs). This report on the U.S. market for OTC GI products presents a description of upper gastrointestinal conditions and diseases, the OTC treatments available, and clinical and business trends affecting the market, consumer behavior and attitudes, and...Published: September 1, 2004 | Price: $895.00 – $1,790.00
Nanotechnology is no longer a bench-top curiosity. It is becoming a real commercial force for a variety of applications. This market briefing discusses the state of play in the race to commercialize products and forecasts likely market scenarios. The briefing forecasts the market in generally promising areas such as cancer therapeutics, specialized drug delivery, diagnostics, and topical therapies, reviewing what companies are doing in those markets.Published: September 1, 2004 | Price: $3,500.00 – $7,000.00
Neural and muscular stimulation by electronic and magnetic means have evolved into a burgeoning product development and commercial fields. For decades, transcutaneous electronic nerve stimulation (TENS) has been a mainstay in the pain relief arsenal. Through the years, as biocompatibility problems were being solved, electrode and sensor implants developed into a multitude of technologies with healthcare applications. The growing approval of these applications by government regulators and the growing acceptance by insurance carriers have driven the market. These techniques have...Published: September 1, 2004 | Price: $3,500.00 – $7,000.00
With an aging population in the United States, the incidence of prevalence of age-related diseases and disorders is expected to mount rapidly over the next decade. Since senior citizens already consume a disproportionate amount of healthcare dollars, the economic picture will only go from bad to worse insofar as healthcare is concerned. The solution to this problem, for this generation and the future, is prevention. The new emphasis on prevention opens up a scope of opportunity in the alternative care...Published: October 1, 2004 | Price: $895.00 – $1,790.00
There is a pressing need for new anticoagulant therapeutics in human medicine. To meet this need, developers are reformulating traditional cornerstone therapeutics such as heparin and looking to new classes such as DTIs to prevent stroke and myocardial infarction and treat deep vein thrombosis and a host of other emerging indications. This briefing analyzes the potential world medical markets for new anticoagulant therapies. Revenue projections through 2010 are made for four geographic regions and for two potentially blockbuster products. This...Published: October 1, 2004 | Price: $995.00 – $1,990.00
The field of pharmacogenetics promises to open up new opportunities for the diagnostic industry at the same time it opens the door to more effective therapeutics. Pharmacogenetics is based on the principle that the effects of a given medication when administered to a patient are determined, at least in part, by his or her genetic constitution. Differences in drug metabolism may lead to varying adverse events or more pronounced adverse events in different individuals, and differing metabolism may also lead...Published: October 1, 2004 | Price: $995.00 – $1,990.00
Currently, the largest market application segment for molecular diagnostics is that for infectious disease testing. The segment is expected to grow at an annual rate between 7% and 8% over the next few years will present some excellent market opportunites for molecular diagnostic competitors. This summary report, extracted from Kalorama Information’s U.S. Market for Molecular Diagnostics, (2nd Edition, May 2004), focuses on the technologies and application of molecular diagnostics in the field of infectious disease testing. The major market effects...Published: October 1, 2004 | Price: $995.00 – $1,990.00
Gene and chromosome testing for inherited diseases currently represents the third largest molecular diagnostics testing segment in the U.S. Assays in this market address applications in genetic carrier and predisposition testing. Currently, most testing is for prenatal screening and for assessing clinically suspect newborns for various chromosomal abnormalities (e.g., Down’s syndrome, fragile X syndrome). Some testing is used for genetic counseling for couples planning to have children. Such diagnostics test for the presence of carrier states of diseases such as...